Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioVentrix Inc.

Minimally invasive and non-surgical treatments for HF

This article was originally published in Start Up

Executive Summary

The most prevalent kind of heart failure is caused by heart attack damage to the left ventricle, and the standard treatment is an open-heart procedure called surgical ventricular restoration. BioVentrix Inc. aims to replace SVR with a less invasive version of the procedure, using its Revivent Myocardial Anchoring System, designed to pull the damaged segments of the left ventricle together to reduce the burden on the non-damaged myocardium and improve its performance.

You may also be interested in...



US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.

Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race

Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.

Novo Mulls What To Do With Wegovy Windfall

The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel